Annabel Samimy
Stock Analyst at Stifel
(4.50)
# 296
Out of 5,133 analysts
55
Total ratings
51.85%
Success rate
35.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $11.34 | +58.73% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $50.32 | +9.30% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $14.94 | +201.20% | 3 | Dec 19, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $35 → $40 | $23.00 | +73.91% | 2 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $32.00 | +62.50% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $36.14 | +38.35% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $21.90 | +119.18% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $179.52 | +28.12% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $81.24 | +10.78% | 2 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $87 → $145 | $103.50 | +40.10% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.02 | +347.76% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.71 | +197.72% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.90 | +127.85% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $14.89 | +61.18% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $30.31 | +163.94% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $162.27 | +41.74% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $5.54 | +351.26% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.43 | +1,578.32% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.04 | +36,664.71% | 3 | Apr 16, 2020 |
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $11.34
Upside: +58.73%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $50.32
Upside: +9.30%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $14.94
Upside: +201.20%
Oculis Holding AG
Dec 19, 2025
Maintains: Buy
Price Target: $35 → $40
Current: $23.00
Upside: +73.91%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $32.00
Upside: +62.50%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $36.14
Upside: +38.35%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $21.90
Upside: +119.18%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $179.52
Upside: +28.12%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $81.24
Upside: +10.78%
Palvella Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $103.50
Upside: +40.10%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.02
Upside: +347.76%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.71
Upside: +197.72%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.90
Upside: +127.85%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $14.89
Upside: +61.18%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $30.31
Upside: +163.94%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $162.27
Upside: +41.74%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $5.54
Upside: +351.26%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.43
Upside: +1,578.32%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.04
Upside: +36,664.71%